文献速递膀胱癌与上尿路尿路上皮癌

机器人辅助根治性肾输尿管切除术后早期单剂丝裂霉素C膀胱灌注的安全性与可行性

Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomy.
PubMed 文献 · BJU Int · 2020-08-09

该研究回顾性分析了69例接受机器人辅助根治性肾输尿管切除术(RARNU)的高危上尿路尿路上皮癌(UUTUC)患者,术中进行膀胱袖状切除、两层水密缝合及膀胱渗漏试验,术后早期(中位第2天)单剂丝裂霉素C(MMC)膀胱灌注。结果显示仅7例(10%)出现Clavien-Dindo I级并发症,30天内无MMC相关不良事件,中位住院2天,所有患者出院时拔除导尿管。表明早期MMC灌注可行且安全,但减少膀胱内复发需纵向随访评估。

要点

  • RARNU术中水密缝合膀胱并验证无渗漏后,术后早期单剂MMC灌注安全可行。
  • 仅10%患者出现Clavien-Dindo I级并发症,30天内无MMC相关不良事件。
  • 中位住院2天,出院时拔除导尿管,早期无导管出院可行。

核心结论

  • RARNU术后立即单剂MMC膀胱灌注可行且安全,无显著不良事件。
  • 早期MMC灌注对膀胱内复发的潜在降低需纵向随访研究评估。

研究设计与样本

  • 回顾性队列研究,纳入69例接受RARNU的UUTUC患者。
  • 手术为标准经腹膜RARNU,包括膀胱袖状切除、两层水密缝合及术中膀胱渗漏试验,无需重新对接机器人系统。

主要发现

  • 中位年龄70岁(IQR 62-78)。
  • MMC灌注中位时间术后第2天(IQR 1-3),中位住院2天(IQR 2-4),所有患者出院时拔除导尿管。
  • 7例(10%)发生Clavien-Dindo I级并发症:5例肠梗阻、1例伤口感染、1例自限性谵妄,均保守处理。
  • 术后30天内未观察到可能与MMC灌注相关的不良事件。

临床怎么用

  • RARNU术中行水密膀胱闭合及渗漏试验后,可考虑术后早期单剂MMC膀胱灌注。
  • 早期灌注支持无导管出院,但需注意Clavien-Dindo I级并发症如肠梗阻。

局限性

  • 回顾性研究设计。
  • 样本量有限(69例)。
  • 缺乏纵向随访数据评估膀胱内复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the safety and feasibility of early single-dose mitomycin C (MMC) bladder instillation after robot-assisted radical nephroureterectomy (RARNU) at a tertiary kidney cancer centre. RARNU with bladder cuff excision and subsequent MMC bladder instillation to reduce recurrence risk is the 'gold standard' for high-risk upper urinary tract urothelial carcinoma (UUTUC). We adapted a RARNU technique with precise distal ureteric dissection, bladder cuff excision and watertight bladder closure. PATIENTS AND METHODS: We retrospectively reviewed all patients undergoing RARNU for UUTUC at our centre performed as a standardised transperitoneal procedure comprising of: bladder cuff excision, two-layer watertight closure and intraoperative bladder leak test; without re-docking/re-positioning of the robotic surgical system. Patient demographics, the timing of MMC instillation, adverse events (surgical and potentially MMC-related) and length of stay (LOS) were assessed according to the Clavien-Dindo classification. RESULTS: A total of 69 patients underwent a RARNU with instillation of MMC. The median (interquartile range [IQR]) age was 70 (62-78) years. The median (IQR) day of MMC instillation was 2 (1-3) days and the median (IQR) LOS was 2 (2-4) days, with urethral catheter removal on day of discharge in all cases. Only Grade I Clavien-Dindo complications occurred in seven patients (10%); five had ileus, one a wound infection and one a self-limiting delirium, all managed conservatively. No adverse events potentially related to MMC instillation were noted within 30 days postoperatively. CONCLUSION: The use of intravesical MMC instillation given in the immediate postoperative period appears feasible and safe in patients undergoing RARNU with intraoperative confirmation of a water-tight closure ensuring early catheter-free discharge, with no significant adverse events. The potential reduction in intravesical recurrence in patients receiving early MMC needs to be assessed with longitudinal follow-up studies.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Gulamhusein A, Silva P, Cullen D, et al. Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomy. BJU Int. 2020. PMID: 32638490. doi:10.1111/bju.15162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。